Synchron

Synchron sells a permanently implantable medical device and, like most active implant manufacturers, would pair it with recurring service and software revenue over the device's life. The Stentrode is a motor neuroprosthesis delivered endovascularly via the jugular vein, avoiding open brain surgery. Synchron generates a one-time hardware sale per implant procedure, paid by hospitals or health systems, with revenue recognized upon implantation. After implant, the company provides ongoing software updates for signal decoding algorithms, system calibration services, and clinical monitoring — these are typically covered under annual service contracts or per-patient subscription fees that generate recurring revenue throughout the device's lifespan. The hardware gross margin structurally mirrors the broader implantable medical-device industry: high per-unit cost of goods (precision manufacturing, biocompatible materials, sterilization) but strong contribution margin once the production line scales. The recurring service layer carries higher incremental margins and improves revenue visibility. R&D and clinical trial costs (regulatory approvals, surgeon training, patient follow-up studies) are the primary upfront investment, subsidized by venture funding and government grants given Synchron's pre-revenue stage. The model is asset-heavy on the manufacturing side but benefits from long device lifespans and lock-in from the implant procedure — explanting is invasive, creating high switching costs.